img

Global Neurodegenerative Disease Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Neurodegenerative Disease Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Neurodegenerative disease or neurodegeneration refers to the progressive damage or wear and tear of the nerve cells. Neurodegenerative disease causes loss of abilities like decision making and eventually memory loss.
Due to the COVID-19 pandemic, the global Neurodegenerative Disease market size was US$ 7003.2 million in 2022 and is forecast to a readjusted size of US$ 8704 million by 2034 with a CAGR of 3.1% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, NMDA accounting for % of the Neurodegenerative Disease global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Parkinson’s Disease segment is altered to an % CAGR throughout this forecast period.
The global key companies of Neurodegenerative Disease include Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA, UCB, Boehringer Ingelheim, Sanofi and GlaxoSmithKline, etc. In 2022, the global top five players had a share approximately % in terms of revenue.
The United States Neurodegenerative Disease market size was US$ million in 2022, while China size was US$ million. The proportion of the United States was % in 2022, while China percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period. As for the Europe Neurodegenerative Disease landscape, Germany is projected to reach US$ million by 2034. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Neurodegenerative Disease market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Neurodegenerative Disease market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Neurodegenerative Disease market. Readers of the report can become informed about current and future trends of the global Neurodegenerative Disease market and how they will impact market growth during the forecast period.



By Company


Novartis
Pfizer
Merck Serono
Biogen Idec
TEVA
UCB
Boehringer Ingelheim
Sanofi
GlaxoSmithKline
Livzon Pharmaceutical
Haisco Pharmaceutical
Jingxin Pharmaceutical
Dongcheng Biochemicals
Hisun Pharmaceutical
Luye Pharma
Ark Pharmaceutical
Kanghong Pharmaceutical
Huahai Pharmaceutical
BORA PHARMACEUTICALS
Segment by Type
NMDA
SSRIs
Dopamine Inhibitors

Segment by Application


Parkinson’s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Alzheimer’s Disease
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Neurodegenerative Disease in global and regional level.
Chapter 3Detailed analysis of Neurodegenerative Disease companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neurodegenerative Disease revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurodegenerative Disease Market Size Growth Rate by Type: 2018 VS 2022 VS 2034
1.2.2 NMDA
1.2.3 SSRIs
1.2.4 Dopamine Inhibitors
1.3 Market by Application
1.3.1 Global Neurodegenerative Disease Market Growth Rate by Application: 2018 VS 2022 VS 2034
1.3.2 Parkinson’s Disease
1.3.3 Huntington Disease
1.3.4 Amyotrophic Lateral Sclerosis
1.3.5 Alzheimer’s Disease
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Neurodegenerative Disease Market Size (2018-2034)
2.2 Neurodegenerative Disease Market Size across Key Geographies Worldwide: 2018 VS 2022 VS 2034
2.3 Global Neurodegenerative Disease Market Size by Region (2018-2024)
2.4 Global Neurodegenerative Disease Market Size Forecast by Region (2024-2034)
2.5 Global Top 10 Neurodegenerative Disease Countries Ranking by Market Size
3 Neurodegenerative Disease Competitive by Company
3.1 Global Neurodegenerative Disease Revenue by Players
3.1.1 Global Neurodegenerative Disease Revenue by Players (2018-2024)
3.1.2 Global Neurodegenerative Disease Market Share by Players (2018-2024)
3.2 Global Neurodegenerative Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Neurodegenerative Disease Revenue
3.4 Global Neurodegenerative Disease Market Concentration Ratio
3.4.1 Global Neurodegenerative Disease Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Disease Revenue in 2022
3.5 Global Key Players of Neurodegenerative Disease Head office and Area Served
3.6 Global Key Players of Neurodegenerative Disease, Product and Application
3.7 Global Key Players of Neurodegenerative Disease, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Neurodegenerative Disease Breakdown Data by Type
4.1 Global Neurodegenerative Disease Historic Revenue by Type (2018-2024)
4.2 Global Neurodegenerative Disease Forecasted Revenue by Type (2024-2034)
5 Global Neurodegenerative Disease Breakdown Data by Application
5.1 Global Neurodegenerative Disease Historic Market Size by Application (2018-2024)
5.2 Global Neurodegenerative Disease Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Neurodegenerative Disease Revenue by Company (2021-2024)
6.2 North America Neurodegenerative Disease Revenue by Type (2018-2034)
6.3 North America Neurodegenerative Disease Revenue by Application (2018-2034)
6.4 North America Neurodegenerative Disease Revenue by Country (2018-2034)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Neurodegenerative Disease Revenue by Company (2021-2024)
7.2 Europe Neurodegenerative Disease Revenue by Type (2018-2034)
7.3 Europe Neurodegenerative Disease Revenue by Application (2018-2034)
7.4 Europe Neurodegenerative Disease Revenue by Country (2018-2034)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Neurodegenerative Disease Revenue by Company (2021-2024)
8.2 Asia Pacific Neurodegenerative Disease Revenue by Type (2018-2034)
8.3 Asia Pacific Neurodegenerative Disease Revenue by Application (2018-2034)
8.4 Asia Pacific Neurodegenerative Disease Revenue by Region (2018-2034)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 China Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
9 Latin America
9.1 Latin America Neurodegenerative Disease Revenue by Company (2021-2024)
9.2 Latin America Neurodegenerative Disease Revenue by Type (2018-2034)
9.3 Latin America Neurodegenerative Disease Revenue by Application (2018-2034)
9.4 Latin America Neurodegenerative Disease Revenue by Country (2018-2034)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Neurodegenerative Disease Revenue by Company (2021-2024)
10.2 Middle East and Africa Neurodegenerative Disease Revenue by Type (2018-2034)
10.3 Middle East and Africa Neurodegenerative Disease Revenue by Application (2018-2034)
10.4 Middle East and Africa Neurodegenerative Disease Revenue by Country (2018-2034)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
11 Company Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Neurodegenerative Disease Products and Services
11.1.4 Novartis Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024)
11.1.5 Novartis Neurodegenerative Disease SWOT Analysis
11.1.6 Novartis Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Neurodegenerative Disease Products and Services
11.2.4 Pfizer Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024)
11.2.5 Pfizer Neurodegenerative Disease SWOT Analysis
11.2.6 Pfizer Recent Development
11.3 Merck Serono
11.3.1 Merck Serono Company Details
11.3.2 Merck Serono Business Overview
11.3.3 Merck Serono Neurodegenerative Disease Products and Services
11.3.4 Merck Serono Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024)
11.3.5 Merck Serono Neurodegenerative Disease SWOT Analysis
11.3.6 Merck Serono Recent Development
11.4 Biogen Idec
11.4.1 Biogen Idec Company Details
11.4.2 Biogen Idec Business Overview
11.4.3 Biogen Idec Neurodegenerative Disease Products and Services
11.4.4 Biogen Idec Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024)
11.4.5 Biogen Idec Neurodegenerative Disease SWOT Analysis
11.4.6 Biogen Idec Recent Development
11.5 TEVA
11.5.1 TEVA Company Details
11.5.2 TEVA Business Overview
11.5.3 TEVA Neurodegenerative Disease Products and Services
11.5.4 TEVA Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024)
11.5.5 TEVA Neurodegenerative Disease SWOT Analysis
11.5.6 TEVA Recent Development
11.6 UCB
11.6.1 UCB Company Details
11.6.2 UCB Business Overview
11.6.3 UCB Neurodegenerative Disease Products and Services
11.6.4 UCB Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024)
11.6.5 UCB Neurodegenerative Disease SWOT Analysis
11.6.6 UCB Recent Development
11.7 Boehringer Ingelheim
11.7.1 Boehringer Ingelheim Company Details
11.7.2 Boehringer Ingelheim Business Overview
11.7.3 Boehringer Ingelheim Neurodegenerative Disease Products and Services
11.7.4 Boehringer Ingelheim Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024)
11.7.5 Boehringer Ingelheim Neurodegenerative Disease SWOT Analysis
11.7.6 Boehringer Ingelheim Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Details
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Neurodegenerative Disease Products and Services
11.8.4 Sanofi Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024)
11.8.5 Sanofi Neurodegenerative Disease SWOT Analysis
11.8.6 Sanofi Recent Development
11.9 GlaxoSmithKline
11.9.1 GlaxoSmithKline Company Details
11.9.2 GlaxoSmithKline Business Overview
11.9.3 GlaxoSmithKline Neurodegenerative Disease Products and Services
11.9.4 GlaxoSmithKline Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024)
11.9.5 GlaxoSmithKline Neurodegenerative Disease SWOT Analysis
11.9.6 GlaxoSmithKline Recent Development
11.10 Livzon Pharmaceutical
11.10.1 Livzon Pharmaceutical Company Details
11.10.2 Livzon Pharmaceutical Business Overview
11.10.3 Livzon Pharmaceutical Neurodegenerative Disease Products and Services
11.10.4 Livzon Pharmaceutical Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024)
11.10.5 Livzon Pharmaceutical Neurodegenerative Disease SWOT Analysis
11.10.6 Livzon Pharmaceutical Recent Development
11.11 Haisco Pharmaceutical
11.11.1 Haisco Pharmaceutical Company Details
11.11.2 Haisco Pharmaceutical Business Overview
11.11.3 Haisco Pharmaceutical Neurodegenerative Disease Products and Services
11.11.4 Haisco Pharmaceutical Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024)
11.11.5 Haisco Pharmaceutical Recent Development
11.12 Jingxin Pharmaceutical
11.12.1 Jingxin Pharmaceutical Company Details
11.12.2 Jingxin Pharmaceutical Business Overview
11.12.3 Jingxin Pharmaceutical Neurodegenerative Disease Products and Services
11.12.4 Jingxin Pharmaceutical Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024)
11.12.5 Jingxin Pharmaceutical Recent Development
11.13 Dongcheng Biochemicals
11.13.1 Dongcheng Biochemicals Company Details
11.13.2 Dongcheng Biochemicals Business Overview
11.13.3 Dongcheng Biochemicals Neurodegenerative Disease Products and Services
11.13.4 Dongcheng Biochemicals Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024)
11.13.5 Dongcheng Biochemicals Recent Development
11.14 Hisun Pharmaceutical
11.14.1 Hisun Pharmaceutical Company Details
11.14.2 Hisun Pharmaceutical Business Overview
11.14.3 Hisun Pharmaceutical Neurodegenerative Disease Products and Services
11.14.4 Hisun Pharmaceutical Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024)
11.14.5 Hisun Pharmaceutical Recent Development
11.15 Luye Pharma
11.15.1 Luye Pharma Company Details
11.15.2 Luye Pharma Business Overview
11.15.3 Luye Pharma Neurodegenerative Disease Products and Services
11.15.4 Luye Pharma Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024)
11.15.5 Luye Pharma Recent Development
11.16 Ark Pharmaceutical
11.16.1 Ark Pharmaceutical Company Details
11.16.2 Ark Pharmaceutical Business Overview
11.16.3 Ark Pharmaceutical Neurodegenerative Disease Products and Services
11.16.4 Ark Pharmaceutical Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024)
11.16.5 Ark Pharmaceutical Recent Development
11.17 Kanghong Pharmaceutical
11.17.1 Kanghong Pharmaceutical Company Details
11.17.2 Kanghong Pharmaceutical Business Overview
11.17.3 Kanghong Pharmaceutical Neurodegenerative Disease Products and Services
11.17.4 Kanghong Pharmaceutical Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024)
11.17.5 Kanghong Pharmaceutical Recent Development
11.18 Huahai Pharmaceutical
11.18.1 Huahai Pharmaceutical Company Details
11.18.2 Huahai Pharmaceutical Business Overview
11.18.3 Huahai Pharmaceutical Neurodegenerative Disease Products and Services
11.18.4 Huahai Pharmaceutical Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024)
11.18.5 Huahai Pharmaceutical Recent Development
11.19 BORA PHARMACEUTICALS
11.19.1 BORA PHARMACEUTICALS Company Details
11.19.2 BORA PHARMACEUTICALS Business Overview
11.19.3 BORA PHARMACEUTICALS Neurodegenerative Disease Products and Services
11.19.4 BORA PHARMACEUTICALS Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024)
11.19.5 BORA PHARMACEUTICALS Recent Development
12 Neurodegenerative Disease Market Dynamics
12.1 Neurodegenerative Disease Industry Trends
12.2 Neurodegenerative Disease Market Drivers
12.3 Neurodegenerative Disease Market Challenges
12.4 Neurodegenerative Disease Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Neurodegenerative Disease Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2022 VS 2034
Table 2. Key Players of NMDA
Table 3. Key Players of SSRIs
Table 4. Key Players of Dopamine Inhibitors
Table 5. Global Neurodegenerative Disease Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2034
Table 6. Global Neurodegenerative Disease Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
Table 7. Global Neurodegenerative Disease Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global Neurodegenerative Disease Revenue Forecast by Region (2024-2034) & (US$ Million)
Table 9. Global Neurodegenerative Disease Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Table 10. Global Neurodegenerative Disease Revenue by Players (2018-2024) & (US$ Million)
Table 11. Global Neurodegenerative Disease Market Share by Players (2018-2024)
Table 12. Global Top Neurodegenerative Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disease as of 2022)
Table 13. Ranking of Global Top Neurodegenerative Disease Companies by Revenue (US$ Million) in 2022
Table 14. Global 5 Largest Players Market Share by Neurodegenerative Disease Revenue (CR5 and HHI) & (2018-2024)
Table 15. Global Key Players of Neurodegenerative Disease, Headquarters and Area Served
Table 16. Global Key Players of Neurodegenerative Disease, Product and Application
Table 17. Global Key Players of Neurodegenerative Disease, Date of Enter into This Industry
Table 18. Mergers & Acquisitions, Expansion Plans
Table 19. Global Neurodegenerative Disease Market Size by Type (2018-2024) & (US$ Million)
Table 20. Global Neurodegenerative Disease Revenue Market Share by Type (2018-2024)
Table 21. Global Neurodegenerative Disease Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 22. Global Neurodegenerative Disease Revenue Market Share by Type (2024-2034)
Table 23. Global Neurodegenerative Disease Market Size by Application (2018-2024) & (US$ Million)
Table 24. Global Neurodegenerative Disease Revenue Market Share by Application (2018-2024)
Table 25. Global Neurodegenerative Disease Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 26. Global Neurodegenerative Disease Revenue Market Share by Application (2024-2034)
Table 27. North America Neurodegenerative Disease Revenue by Company (2021-2024) & (US$ Million)
Table 28. North America Neurodegenerative Disease Revenue by Type (2018-2024) & (US$ Million)
Table 29. North America Neurodegenerative Disease Revenue by Type (2024-2034) & (US$ Million)
Table 30. North America Neurodegenerative Disease Revenue by Application (2018-2024) & (US$ Million)
Table 31. North America Neurodegenerative Disease Revenue by Application (2024-2034) & (US$ Million)
Table 32. North America Neurodegenerative Disease Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 33. North America Neurodegenerative Disease Revenue by Country (2018-2024) & (US$ Million)
Table 34. North America Neurodegenerative Disease Revenue by Country (2024-2034) & (US$ Million)
Table 35. Europe Neurodegenerative Disease Revenue by Company (2021-2024) & (US$ Million)
Table 36. Europe Neurodegenerative Disease Revenue by Type (2018-2024) & (US$ Million)
Table 37. Europe Neurodegenerative Disease Revenue by Type (2024-2034) & (US$ Million)
Table 38. Europe Neurodegenerative Disease Revenue by Application (2018-2024) & (US$ Million)
Table 39. Europe Neurodegenerative Disease Revenue by Application (2024-2034) & (US$ Million)
Table 40. Europe Neurodegenerative Disease Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 41. Europe Neurodegenerative Disease Revenue by Country (2018-2024) & (US$ Million)
Table 42. Europe Neurodegenerative Disease Revenue by Country (2024-2034) & (US$ Million)
Table 43. Asia Pacific Neurodegenerative Disease Revenue by Company (2021-2024) & (US$ Million)
Table 44. Asia Pacific Neurodegenerative Disease Revenue by Type (2018-2024) & (US$ Million)
Table 45. Asia Pacific Neurodegenerative Disease Revenue by Type (2024-2034) & (US$ Million)
Table 46. Asia Pacific Neurodegenerative Disease Revenue by Application (2018-2024) & (US$ Million)
Table 47. Asia Pacific Neurodegenerative Disease Revenue by Application (2024-2034) & (US$ Million)
Table 48. Asia-Pacific Neurodegenerative Disease Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 49. Asia Pacific Neurodegenerative Disease Revenue by Region (2018-2024) & (US$ Million)
Table 50. Asia Pacific Neurodegenerative Disease Revenue by Region (2024-2034) & (US$ Million)
Table 51. Latin America Neurodegenerative Disease Revenue by Company (2021-2024) & (US$ Million)
Table 52. Latin America Neurodegenerative Disease Revenue by Type (2018-2024) & (US$ Million)
Table 53. Latin America Neurodegenerative Disease Revenue by Type (2024-2034) & (US$ Million)
Table 54. Latin America Neurodegenerative Disease Revenue by Application (2018-2024) & (US$ Million)
Table 55. Latin America Neurodegenerative Disease Revenue by Application (2024-2034) & (US$ Million)
Table 56. Latin America Neurodegenerative Disease Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 57. Latin America Neurodegenerative Disease Revenue by Country (2018-2024) & (US$ Million)
Table 58. Latin America Neurodegenerative Disease Revenue by Country (2024-2034) & (US$ Million)
Table 59. Middle East and Africa Neurodegenerative Disease Revenue by Company (2021-2024) & (US$ Million)
Table 60. Middle East and Africa Neurodegenerative Disease Revenue by Type (2018-2024) & (US$ Million)
Table 61. Middle East and Africa Neurodegenerative Disease Revenue by Type (2024-2034) & (US$ Million)
Table 62. Middle East and Africa Neurodegenerative Disease Revenue by Application (2018-2024) & (US$ Million)
Table 63. Middle East and Africa Neurodegenerative Disease Revenue by Application (2024-2034) & (US$ Million)
Table 64. Middle East and Africa Neurodegenerative Disease Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 65. Middle East and Africa Neurodegenerative Disease Revenue by Country (2018-2024) & (US$ Million)
Table 66. Middle East and Africa Neurodegenerative Disease Revenue by Country (2024-2034) & (US$ Million)
Table 67. Novartis Company Details
Table 68. Novartis Business Overview
Table 69. Novartis Neurodegenerative Disease Product and Services
Table 70. Novartis Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 71. Novartis Neurodegenerative Disease SWOT Analysis
Table 72. Novartis Recent Development
Table 73. Pfizer Company Details
Table 74. Pfizer Business Overview
Table 75. Pfizer Neurodegenerative Disease Product and Services
Table 76. Pfizer Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 77. Pfizer Neurodegenerative Disease SWOT Analysis
Table 78. Pfizer Recent Development
Table 79. Merck Serono Company Details
Table 80. Merck Serono Business Overview
Table 81. Merck Serono Neurodegenerative Disease Product and Services
Table 82. Merck Serono Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 83. Merck Serono Neurodegenerative Disease SWOT Analysis
Table 84. Merck Serono Recent Development
Table 85. Biogen Idec Company Details
Table 86. Biogen Idec Business Overview
Table 87. Biogen Idec Neurodegenerative Disease Product and Services
Table 88. Biogen Idec Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 89. Biogen Idec Neurodegenerative Disease SWOT Analysis
Table 90. Biogen Idec Recent Development
Table 91. TEVA Company Details
Table 92. TEVA Business Overview
Table 93. TEVA Neurodegenerative Disease Product and Services
Table 94. TEVA Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 95. TEVA Neurodegenerative Disease SWOT Analysis
Table 96. TEVA Recent Development
Table 97. UCB Company Details
Table 98. UCB Business Overview
Table 99. UCB Neurodegenerative Disease Product and Services
Table 100. UCB Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 101. UCB Neurodegenerative Disease SWOT Analysis
Table 102. UCB Recent Development
Table 103. Boehringer Ingelheim Company Details
Table 104. Boehringer Ingelheim Business Overview
Table 105. Boehringer Ingelheim Neurodegenerative Disease Product and Services
Table 106. Boehringer Ingelheim Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 107. Boehringer Ingelheim Neurodegenerative Disease SWOT Analysis
Table 108. Boehringer Ingelheim Recent Development
Table 109. Sanofi Company Details
Table 110. Sanofi Business Overview
Table 111. Sanofi Neurodegenerative Disease Product and Services
Table 112. Sanofi Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 113. Sanofi Neurodegenerative Disease SWOT Analysis
Table 114. Sanofi Recent Development
Table 115. GlaxoSmithKline Company Details
Table 116. GlaxoSmithKline Business Overview
Table 117. GlaxoSmithKline Neurodegenerative Disease Product and Services
Table 118. GlaxoSmithKline Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 119. GlaxoSmithKline Neurodegenerative Disease SWOT Analysis
Table 120. GlaxoSmithKline Recent Development
Table 121. Livzon Pharmaceutical Company Details
Table 122. Livzon Pharmaceutical Business Overview
Table 123. Livzon Pharmaceutical Neurodegenerative Disease Product and Services
Table 124. Livzon Pharmaceutical Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 125. Livzon Pharmaceutical Neurodegenerative Disease SWOT Analysis
Table 126. Livzon Pharmaceutical Recent Development
Table 127. Haisco Pharmaceutical Company Details
Table 128. Haisco Pharmaceutical Business Overview
Table 129. Haisco Pharmaceutical Neurodegenerative Disease Product and Services
Table 130. Haisco Pharmaceutical Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 131. Haisco Pharmaceutical Recent Development
Table 132. Jingxin Pharmaceutical Company Details
Table 133. Jingxin Pharmaceutical Business Overview
Table 134. Jingxin Pharmaceutical Neurodegenerative Disease Product and Services
Table 135. Jingxin Pharmaceutical Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 136. Jingxin Pharmaceutical Recent Development
Table 137. Dongcheng Biochemicals Company Details
Table 138. Dongcheng Biochemicals Business Overview
Table 139. Dongcheng Biochemicals Neurodegenerative Disease Product and Services
Table 140. Dongcheng Biochemicals Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 141. Dongcheng Biochemicals Recent Development
Table 142. Hisun Pharmaceutical Company Details
Table 143. Hisun Pharmaceutical Business Overview
Table 144. Hisun Pharmaceutical Neurodegenerative Disease Product and Services
Table 145. Hisun Pharmaceutical Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 146. Hisun Pharmaceutical Recent Development
Table 147. Luye Pharma Company Details
Table 148. Luye Pharma Business Overview
Table 149. Luye Pharma Neurodegenerative Disease Product and Services
Table 150. Luye Pharma Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 151. Luye Pharma Recent Development
Table 152. Ark Pharmaceutical Company Details
Table 153. Ark Pharmaceutical Business Overview
Table 154. Ark Pharmaceutical Neurodegenerative Disease Product and Services
Table 155. Ark Pharmaceutical Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 156. Ark Pharmaceutical Recent Development
Table 157. Kanghong Pharmaceutical Company Details
Table 158. Kanghong Pharmaceutical Business Overview
Table 159. Kanghong Pharmaceutical Neurodegenerative Disease Product and Services
Table 160. Kanghong Pharmaceutical Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 161. Kanghong Pharmaceutical Recent Development
Table 162. Huahai Pharmaceutical Company Details
Table 163. Huahai Pharmaceutical Business Overview
Table 164. Huahai Pharmaceutical Neurodegenerative Disease Product and Services
Table 165. Huahai Pharmaceutical Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 166. Huahai Pharmaceutical Recent Development
Table 167. BORA PHARMACEUTICALS Company Details
Table 168. BORA PHARMACEUTICALS Business Overview
Table 169. BORA PHARMACEUTICALS Neurodegenerative Disease Product and Services
Table 170. BORA PHARMACEUTICALS Neurodegenerative Disease Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 171. BORA PHARMACEUTICALS Recent Development
Table 172. Neurodegenerative Disease Market Trends
Table 173. Neurodegenerative Disease Market Drivers
Table 174. Neurodegenerative Disease Market Challenges
Table 175. Neurodegenerative Disease Market Restraints
Table 176. Research Programs/Design for This Report
Table 177. Key Data Information from Secondary Sources
Table 178. Key Data Information from Primary Sources
List of Figures
Figure 1. Neurodegenerative Disease Product Picture
Figure 2. Global Neurodegenerative Disease Market Size by Type (US$ Million): 2018 VS 2022 VS 2034
Figure 3. Global Neurodegenerative Disease Market Share by Type: 2022 VS 2034
Figure 4. NMDA Features
Figure 5. SSRIs Features
Figure 6. Dopamine Inhibitors Features
Figure 7. Global Neurodegenerative Disease Market Size by Application (US$ Million): 2018 VS 2022 VS 2034
Figure 8. Global Neurodegenerative Disease Market Share by Application: 2022 VS 2034
Figure 9. Parkinson’s Disease
Figure 10. Huntington Disease
Figure 11. Amyotrophic Lateral Sclerosis
Figure 12. Alzheimer’s Disease
Figure 13. Neurodegenerative Disease Report Years Considered
Figure 14. Global Neurodegenerative Disease Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 15. Global Neurodegenerative Disease Market Size 2018-2034 (US$ Million)
Figure 16. Global Neurodegenerative Disease Market Size Market Share by Region: 2022 VS 2034
Figure 17. Global Neurodegenerative Disease Revenue Market Share by Region in 2018 VS 2022
Figure 18. Global Neurodegenerative Disease Revenue Market Share Forecast by Region (2024-2034)
Figure 19. Global Top 10 Neurodegenerative Disease Countries Ranking by Market Size (US$ Million) in 2022
Figure 20. Global Neurodegenerative Disease Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Figure 21. Global Neurodegenerative Disease Market Share by Players in 2022
Figure 22. Global Top Neurodegenerative Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disease as of 2022)
Figure 23. The Top 10 and 5 Players Market Share by Neurodegenerative Disease Revenue in 2022
Figure 24. North America Neurodegenerative Disease Revenue Market Share by Company in 2022
Figure 25. North America Neurodegenerative Disease Revenue Market Share by Type (2018-2034)
Figure 26. North America Neurodegenerative Disease Revenue Market Share by Application (2018-2034)
Figure 27. North America Neurodegenerative Disease Revenue Share by Country (2018-2034)
Figure 28. United States Neurodegenerative Disease Revenue (2018-2034) & (US$ Million)
Figure 29. Canada Neurodegenerative Disease Revenue (2018-2034) & (US$ Million)
Figure 30. Europe Neurodegenerative Disease Revenue Market Share by Company in 2022
Figure 31. Europe Neurodegenerative Disease Revenue Market Share by Type (2018-2034)
Figure 32. Europe Neurodegenerative Disease Revenue Market Share by Application (2018-2034)
Figure 33. Europe Neurodegenerative Disease Revenue Share by Country (2018-2034)
Figure 34. Germany Neurodegenerative Disease Revenue (2018-2034) & (US$ Million)
Figure 35. France Neurodegenerative Disease Revenue (2018-2034) & (US$ Million)
Figure 36. U.K. Neurodegenerative Disease Revenue (2018-2034) & (US$ Million)
Figure 37. Italy Neurodegenerative Disease Revenue (2018-2034) & (US$ Million)
Figure 38. Russia Neurodegenerative Disease Revenue (2018-2034) & (US$ Million)
Figure 39. Asia Pacific Neurodegenerative Disease Revenue Market Share by Company in 2022
Figure 40. Asia Pacific Neurodegenerative Disease Revenue Market Share by Type (2018-2034)
Figure 41. Asia Pacific Neurodegenerative Disease Revenue Market Share by Application (2018-2034)
Figure 42. Asia Pacific Neurodegenerative Disease Revenue Share by Region (2018-2034)
Figure 43. China Neurodegenerative Disease Revenue (2018-2034) & (US$ Million)
Figure 44. Japan Neurodegenerative Disease Revenue (2018-2034) & (US$ Million)
Figure 45. South Korea Neurodegenerative Disease Revenue (2018-2034) & (US$ Million)
Figure 46. India Neurodegenerative Disease Revenue (2018-2034) & (US$ Million)
Figure 47. Australia Neurodegenerative Disease Revenue (2018-2034) & (US$ Million)
Figure 48. China Taiwan Neurodegenerative Disease Revenue (2018-2034) & (US$ Million)
Figure 49. Indonesia Neurodegenerative Disease Revenue (2018-2034) & (US$ Million)
Figure 50. Thailand Neurodegenerative Disease Revenue (2018-2034) & (US$ Million)
Figure 51. Malaysia Neurodegenerative Disease Revenue (2018-2034) & (US$ Million)
Figure 52. Latin America Neurodegenerative Disease Revenue Market Share by Company in 2022
Figure 53. Latin America Neurodegenerative Disease Revenue Market Share by Type (2018-2034)
Figure 54. Latin America Neurodegenerative Disease Revenue Market Share by Application (2018-2034)
Figure 55. Latin America Neurodegenerative Disease Revenue Share by Country (2018-2034)
Figure 56. Mexico Neurodegenerative Disease Revenue (2018-2034) & (US$ Million)
Figure 57. Brazil Neurodegenerative Disease Revenue (2018-2034) & (US$ Million)
Figure 58. Argentina Neurodegenerative Disease Revenue (2018-2034) & (US$ Million)
Figure 59. Middle East and Africa Neurodegenerative Disease Revenue Market Share by Company in 2022
Figure 60. Middle East and Africa Neurodegenerative Disease Revenue Market Share by Type (2018-2034)
Figure 61. Middle East and Africa Neurodegenerative Disease Revenue Market Share by Application (2018-2034)
Figure 62. Middle East and Africa Neurodegenerative Disease Revenue Share by Country (2018-2034)
Figure 63. Turkey Neurodegenerative Disease Revenue (2018-2034) & (US$ Million)
Figure 64. Saudi Arabia Neurodegenerative Disease Revenue (2018-2034) & (US$ Million)
Figure 65. UAE Neurodegenerative Disease Revenue (2018-2034) & (US$ Million)
Figure 66. Novartis Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 67. Pfizer Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 68. Merck Serono Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 69. Biogen Idec Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 70. TEVA Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 71. UCB Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 72. Boehringer Ingelheim Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 73. Sanofi Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 74. GlaxoSmithKline Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 75. Livzon Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 76. Haisco Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 77. Jingxin Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 78. Dongcheng Biochemicals Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 79. Hisun Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 80. Luye Pharma Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 81. Ark Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 82. Kanghong Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 83. Huahai Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 84. BORA PHARMACEUTICALS Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 85. Bottom-up and Top-down Approaches for This Report
Figure 86. Data Triangulation
Figure 87. Key Executives Interviewed